Centers for Disease Control and Prevention - ERA

Description

Chronic hepatitis B and C represent a major health problem for the United States. Approximately 3.2 million Americans are chronically infected with hepatitis C virus and 1.25 million with chronic hepatitis B virus, with an estimated 55,000 hepatitis C virus- related deaths and 2,000-4,000 hepatitis B related deaths each year. Data from longitudinal cohorts of patients with chronic hepatitis B and C virus infection are needed to understand the spectrum of disease, the natural history, and the public health impact of chronic viral hepatitis. The purpose of this cooperative agreement is to understand the effectiveness, cost, benefits, and adverse effects of evolving antiviral therapy for hepatitis B virus infection and hepatitis C virus infection on a population basis.

Who can apply

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities / Indian housing authorities
• Native American tribal organizations (other than Federally recognized)
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Contact

Deborah Loveys<br/>hft6@cdc.gov<br/>
hft6@cdc.gov